Adding blood pressure drug to standard antibiotics speeds up TB treatment

August 29, 2013

Infectious disease experts at Johns Hopkins have found, in studies in mice, that a drug better known as a treatment for high blood pressure and headaches effectively speeds up treatment of TB when added to the standard, daily antibiotic regimen. Test animals were cured in four months instead of the usual six.

Researchers say that if clinical trials starting later this year in India, a country heavily burdened by the highly contagious lung disease, prove successful, then the shortened time with verapamil, a so-called , used in combination with antibiotics isoniazid and rifampin, could make it easier for infected people to complete their therapy as prescribed. The experts note that antibiotics for TB do not work if treatment is interrupted or if people stop taking their medication. Improved drug adherence, they say, could also prevent the buildup of drug- of TB, caused by Mycobacterium tuberculosis, which is now estimated to kill a million people each year, mostly in the developing world.

"Our results show that verapamil is a good drug candidate as an add-on therapy with antibiotics for TB, a in urgent need of new treatment options," says study senior investigator and infectious disease specialist William Bishai, M.D., Ph.D. Bishai's team's latest findings are set to be published in the Sept. 1 edition of the American Journal of Respiratory and Critical Care Medicine.

Bishai, a professor at the Johns Hopkins University School of Medicine and its Center for Tuberculosis Research, says that drug treatment options for TB are "too few," and limited to about a dozen older antibiotics, some with serious side effects. Bishai, who also is a Howard Hughes Medical Institute Lab Head at Johns Hopkins, says verapamil has been around for some 40 years, so its side effects—such as too-—are well-known. He says the clinical trial in India, primarily a safety study to determine a minimum effective dose, will be pivotal in clarifying the drug's "true potential" as an add-on therapy in TB.

Lead study investigator and immunologist Shashank Gupta, Ph.D., says the study results also suggest that verapamil, commonly sold under the brand names Isoptin, Verelan, Calan, Bosoptin and Covera, could be a good for combination therapy studies with multidrug-resistant forms of TB.

Gupta, a postdoctoral fellow at Johns Hopkins, says verapamil is known to work as an efflux pump inhibitor, making bacteria more susceptible to antibiotics and killing by immune cell macrophages, but whose precise workings remain unknown. He says the research team investigated verapamil's potential as a TB therapy after another study showed that increased efflux pump action promoted drug tolerance to TB, minimizing antibiotics' effectiveness.

Among the latest study's other key findings were that verapamil accelerated killing of TB bacteria 10-fold after two months of treatment. After four months of therapy, half of the lung tissue samples from mice receiving verapamil had zero bacterial counts, while all tissue samples in mice not on the blood pressure medication were still positive for TB.

In the study, performed at Johns Hopkins from January to November 2012, mice infected with TB were treated with a standard antibiotic regimen of daily doses of isoniazid, rifampin and pyrazinamide for two months, followed by daily doses of just isoniazid and rifampin for four months. Half of the infected mice also received daily doses of verapamil, equivalent to the minimum dose manufactured for use in humans, at 40 milligrams per liter of blood, for the entire six months. Researchers calculated a 50 percent increase in the original dosage of verapamil used in the study to compensate for rifampin's acceleration of verapamil's breakdown in the body. Both groups of mice had lung tissue analyses performed at least monthly.

Explore further: Growing presence of drug-resistant tuberculosis fuels need for faster development of new combination therapies

Related Stories

Potential new drug for tuberculosis

August 5, 2013

A new drug capable of inhibiting growth of Mycobacterium tuberculosis is reported this week in Nature Medicine. The findings may improve therapeutic options for the treatment of drug resistant tuberculosis (TB).

New hope for improved TB treatments

August 9, 2013

Researchers at the University of Southampton have identified new markers of tuberculosis (TB) that may help in the development of new diagnostic tests and treatments.

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...

Computer model reveals deadly route of Ebola outbreak

November 10, 2015

Using a novel statistical model, a research team led by Columbia University's Mailman School of Public Health mapped the spread of the 2014-2015 Ebola outbreak in Sierra Leone, providing the most detailed picture to date ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Aug 29, 2013
Calcium channel blockers have been shown to be protect from iron, iron reduction is being recommended for tuberculosis and antibiotics bind iron.
"Excess extracellular iron may enter cells via nontraditional routes such as voltage-gated calcium channels "
"Iron enhances Mycobacterium tuberculosis infection"
"Association of Pulmonary Tuberculosis with Increased Dietary Iron"
"Three tetracyclines (tetracycline, doxycycline, and minocycline) were found to possess iron-chelating activity "

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.